by Joris | Apr 24, 2026 | Blog, News, Person, SURE Technology
Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance. As the cell and gene therapy (CGT) space matures and commoditizes, many low-hanging fruits have been picked. We are now facing another frontier in biology: getting a...
by Joris | Feb 17, 2026 | Blog, News, Person, SURE Technology
VectorY’s Clinical Milestone and the Shift Towards Experimentally Validated Promoters This week, the ALS community reached a significant milestone. Our partner, VectorY Therapeutics, announced the first patient has been dosed in their Phase 1/2 PIONEER-ALS clinical...
by Joris | Jan 28, 2026 | Blog, News, Person, SURE Technology
JURA Bio and Annogen Announce Research Collaboration to Advance Precision Gene Expression Engineering Through AI-Driven Design and Functional Genomics Partnership brings together JURA’s variational synthesis platform and Annogen’s SuRE™ technology to...
by Joris | Jan 26, 2026 | Application notes, Blog, News, Person, SURE Technology
Twist Webinar: Bespoke Functional Genomics for AI Presented by Dr. Joris van Arensbergen Founder & CEO, Annogen Covered in this Webinar How Annogen generates SuRE™ datasets that support the design of DNA regulatory element How combined with Twist Bioscience’s...
by Joris | Dec 11, 2025 | Blog, News, SURE Technology
Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the...
by Joris | Dec 4, 2025 | Blog, News, SURE Technology
Annogen is excited to confirm our attendance at the upcoming Advanced Therapies Congress, scheduled for March 17th – 18th, 2026, at ExCeL London! We invite you to schedule a meeting to learn more about how Annogen can support your research and development efforts. Our...
